Related Experiment Video

Updated: Jan 17, 2026

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.2K

Association between SGLT2 inhibitors and genital cancer: a meta-analysis and mendelian randomization study

Bo Xu1,2,3,4,5,6, Yilin Liu1,2,3,4,6, Zunbo He7,8,9,10

  • 1The First Affiliated Hospital, Hunan Provincial Clinical Medical Research Center for Drug Evaluation of Major Chronic Diseases, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.

Journal of Endocrinological Investigation
|September 18, 2025
PubMed
Abstract

Insights

Sodium-glucose cotransporter 2 (SGLT2) inhibitors show a neutral risk for most genital cancers. However, SGLT2 inhibition may reduce cervical cancer risk, according to genetic evidence.

Area of Science:

  • Oncology
  • Pharmacology
  • Genetics

Background:

  • The association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and genital cancer risk is not well-established.
  • This study addresses the uncertainty surrounding SGLT2 inhibitors' effects on various genital cancers.

Purpose of the Study:

  • To investigate the impact of SGLT2 inhibitors and SGLT2 inhibition on the risk of developing genital cancers.
  • To analyze the safety profile of SGLT2 inhibitors concerning oncological outcomes in the genital region.

Main Methods:

  • Systematic literature search of major databases (PubMed, Web of Science, clinical trial registries) for large randomized controlled trials.
  • Meta-analysis using Mantel-Haenszel methods to calculate risk ratios (RRs) and odds ratios (ORs) with 95% confidence intervals (CIs).
  • Mendelian randomization study utilizing genetic variants in SLC5A2 to assess causal relationships between SGLT2 inhibition and genital cancers.

Main Results:

  • SGLT2 inhibitors demonstrated a neutral overall risk for genital cancers (RR 1.10; 95% CI 0.93-1.31) across 15 studies (16 trials) with 101,430 patients.
  • No significant effects were observed for cervical, endometrial, ovarian, prostate, uterine, penile, or vulvar cancers; however, dapagliflozin showed a potential increase in male genital cancer risk (RR 1.31; 95% CI 0.99-1.74).
  • SGLT2 inhibition significantly reduced testicular cancer risk (OR 0.012; 95% CI 0.001-0.220) and demonstrated a strong protective effect against cervical cancer (OR 0.013; 95% CI 0.001-0.122).

Conclusions:

  • Sodium-glucose cotransporter 2 (SGLT2) inhibitors have a neutral overall risk profile for genital cancers.
  • Genetic evidence strongly supports a beneficial effect of SGLT2 inhibition in reducing cervical cancer risk.
  • Further research may be warranted to explore specific drug effects and mechanisms in different genital cancer types.
Keywords:
Cervical cancerGenital cancerSGLT2 inhibitionSGLT2 inhibitors

More Related Videos

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

648
An Orthotopic Murine Model of Human Prostate Cancer Metastasis06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

35.8K

Related Concept Videos

Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
15.3K
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.9K
Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
7.7K